Furthermore, Riaz et al. reported that patients with recurrent SERPINB3 and SERPINB4 mutations respond to anti-CTLA4 immunotherapy [39], which demonstrates the potential of SERPINB3 to serve as a response signature in melanoma. Here, SERPINB4 is linked to melanoma.